JNJ - Johnson & Johnson
| Previous Close | 145.91 |
| Open | 145.49 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 144.12 - 147.34 |
| 52 Week Range | 118.62 - 148.99 |
| Volume | 9,444,459 |
| Avg. Volume | 7,169,367 |
| Market Cap | 390.04B |
| Beta (3Y Monthly) | 0.32 |
| PE Ratio (TTM) | 255.59 |
| EPS (TTM) | 0.57 |
| Earnings Date | Jan 22, 2019 |
| Forward Dividend & Yield | 3.60 (2.48%) |
| Ex-Dividend Date | 2018-11-26 |
| 1y Target Est | 148.11 |
- Insider Monkey•2 hours ago
Is Johnson & Johnson (JNJ) A Good Stock According To Hedge Funds?
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
- Motley Fool•7 hours ago
Here's Why BeiGene Stock Rose 21.7% in November
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.
- Kiplinger•3 days ago
19 Best Stocks to Buy for 2019
Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock picks. Investors looking for the best stocks to buy for 2019 should start with these 19 companies. These firms, ranging from a money-center bank to a bargain-basement retailer, have solid prospects in 2019. We've also listed five stocks you should consider parting ways with. Check them out. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
- Reuters•3 days ago
PRESS DIGEST-New York Times business news - Dec 7
The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The ride-hailing company Lyft said on Thursday it ...
- InvestorPlace•3 days ago
7 Dividend Titans Trading Like Growth Stocks
- Zacks•3 days ago
Johnson & Johnson (JNJ) Stock Moves -0.08%: What You Should Know
Johnson & Johnson (JNJ) closed at $145.91 in the latest trading session, marking a -0.08% move from the prior day.
- InvestorPlace•3 days ago
Can You Hide in Johnson and Johnson Stock Amid the Turmoil?
Markets gave investors quite a pump fake earlier this week. After the strong rally on Monday, investors believed that stocks would have a relief rally heading into 2019. While the action caused investors’ sentiment to drop sharply, not all stocks had a horrible day.
- Reuters•3 days ago
J&J unit to pay $360 million to U.S. to resolve charity kickback probe
A Johnson & Johnson (JNJ.N) unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday. The settlement with Actelion Pharmaceuticals US Inc, which became a subsidiary of J&J following a 2017 acquisition, was the largest so far to result from an industry-wide probe into drugmakers' support of patient assistance charities. The government said Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co-pay obligations of thousands of Medicare patients using its pulmonary artery hypertension treatments Tracleer, Ventavis, Veletri and Opsumit.
Reuters•3 days agoJ&J unit to pay $360 million to U.S. to resolve charity kickback probe
A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday. The settlement with Actelion Pharmaceuticals US Inc, which became a subsidiary of J&J following a 2017 acquisition, was the largest so far to result from an industry-wide probe into drugmakers' support of patient assistance charities. The government said Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co-pay obligations of thousands of Medicare patients using its pulmonary artery hypertension treatments Tracleer, Ventavis, Veletri and Opsumit.
- American City Business Journals•3 days ago
Peninsula drug maker to pay $360M to settle Justice Department claims
The company gave a nonprofit foundation money to cover Medicare copays for its pulmonary arterial hypertension drugs as it hiked the prices of those drugs and steered Medicare patients away from the company's own free drug program to the foundation.
- American City Business Journals•3 days ago
Houston cancer pharma co. begins Phase I trials after $6M Series B
Iterion Therapeutics rebranded itself from Beta Cat Pharmaceuticals in the last week or two, according to president and CEO Rahul Aras.
- Associated Press•3 days ago
Drug company Actelion to pay $360M in kickback probe
BOSTON (AP) — A pharmaceutical company has agreed to pay $360 million to resolve allegations that it used a charitable foundation to pay kickbacks to Medicare patients.
- Market Realist•3 days ago
Where Does Apple Rank in the Wearables Market?
Apple (AAPL) ventured into selling wearable devices such as smartwatches to diversify its hardware business beyond the mature markets for smartphones and personal computers. Xiaomi shipped 6.9 million wearables, representing a 21.5% share of the global market. Some 32 million wearable devices were shipped globally in the third quarter, showing that the wearables market had expanded 21.7% YoY in the period.
- Zacks•4 days ago
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
- Financial Times•4 days ago
[$$] Actelion Pharmaceuticals agrees to pay $360m in DoJ settlement
has agreed to pay $360m to settle civil claims it used a charity to pay illegal kickbacks to patients in the US, the Department of Justice announced on Thursday. last year, was accused of using a charitable foundation to help Medicare patients make payments for its prescription drugs that treat high blood pressure. The settlement on Thursday is the largest agreed so far in the US government’s investigation of the use of charitable foundations in the pharmaceutical industry.
- GuruFocus.com•4 days ago
Johnson & Johnson: An Excellent Business Selling at a Rational Price
Warning! GuruFocus has detected 2 Warning Sign with HA. When you read something like that, a company like Johnson & Johnson (JNJ) comes to mind. Johnson & Johnson has grown earnings per share by a compound annual rate of 10.5% per year over the last two decades, by 6% per annum in the last decade and 8.2% annualized over the last five years.
- Zacks•5 days ago
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
- Zacks•5 days ago
Mylan Expands Recall of Valsartan to All Unexpired Lots
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
- Motley Fool•5 days ago
Can Celgene and bluebird bio Survive a Two-Pronged Attack?
A promising program these partners are working on is under assault from two different directions.
- InvestorPlace•5 days ago
10 Defensive Stocks to Protect Your Portfolio in 2019
Following the highly anticipated sit-down between President Donald Trump and Chinese President Xi Jinping at the G-20 summit, investors received a respite: the White House says both leaders agreed to temporarily halt escalating sanctions. Trump has never enjoyed a reputation as a steady, calm hand in the face of stress or provocation. While the agreement facilitates a 90-day ceasefire regarding the ongoing trade war, investors should adopt a measured approach.
- Zacks•5 days ago
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
- TheStreet.com•5 days ago
P&G, Johnson & Johnson, Verizon Hold Strongest on Ugly Day for Dow Jones
The U.S. stock market was getting rocked Tuesday, as investors grew wary of the promising trade talks that came out of the G-20 meeting and the inverted 3-year and 5-year treasury yields. But there's a clear sign of where investors' appetite could soon be headed atop the leader board.
- Motley Fool•5 days ago
Better Buy: Intuitive Surgical vs. Johnson & Johnson
Are aging boomers a bigger boon to a robotic surgery leader or a century-old healthcare conglomerate?
